| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Epithelioid sarcoma (EPS) is a highly malignant soft tissue tumor which is difficult to diagnose in some cases. EPS usually does not respond well to chemotherapy or radiotherapy; therefore, a novel therapeutic option needs to be developed. We analyzed the characteristics of cancer stem-like cells/cancer-initiating cells in EPS cell lines (FU-EPS-1 and SFT-8606). We isolated a subpopulation of cancer stem-like cells in the FU-EPS-1 cell line. In addition, we found that high-molecular weight glycoprotein CA125 would be a useful marker for monitoring the clinical course of EPS. Furthermore, we identified characteristic chromosomal aberrations in a variety of soft tissue tumors.
|
